Committed, tireless, and persistent.
We are committed to the discovery, development, and commercialization of a transformational generation of targeted therapies for women’s cancers.
Our team spent more than a decade conducting research, and has a deep insight into, endocrine-driven cancers. OP-1250 was the result of that persistence–the first compound designed to realize the Olema vision.
Our Team
leadership
board of directors
leadership
board of directors
leadership
Sean P. Bohen, M.D., Ph.D.
President and CEO
Cyrus Harmon, Ph.D.
Chief Technology Officer
Pamela M. Klein, M.D.
Chief Medical Officer
Peter Kushner, Ph.D.
Chief Scientific Officer
Shane Kovacs
Chief Operating and Financial Officer
David C. Myles, Ph.D.
Chief Development Officer
Kinney Horn
Chief Business Officer
John B. Moriarty Jr., J.D.
Executive Vice President and Chief Legal Officer
Leslie Hodges Gallagher, Ph.D.
Senior Vice President, Discovery Biology
Sean P. Bohen, M.D., Ph.D.
President and CEO
Ian Clark
Chairman of the Board
Cindy Butitta
Member
Sandra J. Horning, M.D., FACP, FASCO
Member
Frank McCormick, Ph.D., F.R.S., D.Sc (Hon)
Member
Andy Rappaport
Member
Gorjan Hrustanovic, Ph.D.
Member
Graham Walmsley, M.D., Ph.D.
Member
Cyrus Harmon, Ph.D.
Chief Technology Officer
Julie Dexter
Vice President and Head of People
Demiana Faltaos, PharmD, Ph.D
Vice President, Head of Clinical Pharmacology
David Kulp, PhD
Vice President, Research Informatics
Florence Zhu, CPA
Vice President, Finance & Controller
Press Releases
Here are the latest press releases from Olema.
For further information, visit Investors & Media.
Here are the latest press releases from Olema.
For further information, visit Investors & Media.
Item 1 of 6